IL17A and pertussis: Novel vaccines that induce both sufficient PT-neutralizing serum antibodies and nasal SIgA together with IL-17-producing TRM cells would therefore be expected to provide long-lived protection against both pertussis disease and colonization by B. pertussis and therefore prevent pertussis spread [56].